## Disclosures

### Personal Commercial (1)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medtronic Inc</td>
<td>Consultant Fees/Honoraria</td>
<td>Significant (&gt;= $5,000)</td>
<td>Invasive CV Angio and Interventions</td>
</tr>
</tbody>
</table>

### Personal Non-Commercial (1)

<table>
<thead>
<tr>
<th>Non-Commercial Entity Name</th>
<th>Relationship Category</th>
<th>Compensation Level</th>
<th>Topic Area(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCAI</td>
<td>Other - On SCAI Ischemic Heart Disease Council</td>
<td>None ($0)</td>
<td></td>
</tr>
</tbody>
</table>

### Clinical Trial Enroller (5)

<table>
<thead>
<tr>
<th>Trial Name</th>
<th>Trial Sponsor</th>
<th>Trial Funding Source</th>
</tr>
</thead>
<tbody>
<tr>
<td>REDUCE LAP-HF RANDOMIZED TRIAL II: A study to evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure</td>
<td>Corvia medical Inc</td>
<td></td>
</tr>
<tr>
<td>Medtronic Low Risk TAVR trial</td>
<td>MEDTRONIC</td>
<td></td>
</tr>
<tr>
<td>Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System in Patients at Low Risk for Surgical Aortic Valve Replacement.</td>
<td>MEDTRONIC</td>
<td></td>
</tr>
<tr>
<td>A prospective, randomized, adaptive, double-blind, sham-controlled, multicenter study to evaluate the ROX Coupler in subjects with hypertension.</td>
<td>Rox Medical, Inc.</td>
<td></td>
</tr>
<tr>
<td>A pragmatiC eStrategy to promote actIVity and Enhance quality of life AFTER Transcatheter Aortic Valve Replacement- SIRB</td>
<td>Vanderbilt University</td>
<td>National Institutes of Health</td>
</tr>
</tbody>
</table>

### Institutional Financial Decision-Making Role (1)

<table>
<thead>
<tr>
<th>Funding Source</th>
<th>Institutional Compensation Level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medtronic Inc</td>
<td>Significant (&gt;= $5,000)</td>
</tr>
</tbody>
</table>

### Expert Witness Testimony (4)

<table>
<thead>
<tr>
<th>Year</th>
<th>Case Title</th>
<th>Represented</th>
<th>Description</th>
<th>Compensation</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>Delay in treatment</td>
<td>Defendant</td>
<td>Patient with acute stent thrombosis</td>
<td>Modest (&lt; $5,000)</td>
</tr>
<tr>
<td>2016</td>
<td>Failure to prescribe</td>
<td>Defendant</td>
<td>Stent thrombosis in patient who failed to fill prescription for DAPT</td>
<td>Modest (&lt; $5,000)</td>
</tr>
<tr>
<td>2015</td>
<td>Negligence</td>
<td>Defendant</td>
<td>Allegation of failure to provide timely revascularization in a STEMI patient with spontaneous coronary artery dissection</td>
<td>Significant (&gt;= $5,000)</td>
</tr>
<tr>
<td>2013</td>
<td>Malpractice</td>
<td>Defendant</td>
<td>Issue of failure to diagnose</td>
<td>Modest (&lt; $5,000)</td>
</tr>
</tbody>
</table>

† Commercial Funding Source  | ‡ Trial Name  

### Agreement

**Certified Education Attestation** | Signed on 2/23/2020
ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College’s integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.